Neurohormone activation

Critical Care Nursing Clinics of North America

Volumn 15, Issue 4, 2003, Pages 413-421

  Piano, Mariann R ^a   Prasun, Marilyn ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Carle Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C; NEUROHORMONE; NORADRENALIN; RENIN; VASOPRESSIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; NATRIURETIC FACTOR; VASOPRESSIN DERIVATIVE;

HEART FAILURE; HEART VENTRICLE REMODELING; HORMONE ACTION; HUMAN; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CONGESTIVE HEART FAILURE; DISEASE COURSE; METABOLISM; PHYSIOLOGY;

ALDOSTERONE; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; RENIN-ANGIOTENSIN SYSTEM; VASOPRESSINS; VENTRICULAR REMODELING;

EID: 1442334422     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-5885(02)00096-5     Document Type: Review

References (58)

1. Piano M.R., Kim S.D., Jarvis C. Cellular events linked to cardiac remodeling in heart failure: targets for pharmacologic intervention. J Cardiovasc Nurs. 14:(4):2000;1-23
2. Maisch B. Ventricular remodeling. Cardiology. 87:(Suppl 1):1996;2-10
3. Bruna R.D., Kurtz A., Schricker K. Regulation of renin synthesis in the juxtaglomerular cells. Curr Opin Nephrol Hyperten. 5:(1):1996;16-19
4. Dzau V.J., Pratt R.E. Renin-angiotensins system. Fozzard H.A., Jennings R.B., Haber E., et al. The heart and cardiovascular system. 1992;1817-1849 Raven Press, New York
5. Rose B.L. Clinical physiology of acid-base and electrolyte disorders. 2001;McGraw Hill, New York
6. Linz W., Wiemer G., Gohlke P., et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49
7. Wollert K.C., Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc Res. 43:(4):1999;838-849
8. Studies of the Left Ventricular Dysfunction (SOLVD). Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:(10):1992;685-691
9. The CONSENSUS Trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316:(23):1987;1429-1435
10. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 82:1990;1724-1729
11. Francis G.S., Cohn J.N., Johnson G., et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFTII. The V-HeFT VA Cooperative Studies Group. Circulation. 87:1993;V140-V148
12. Swedberg K., Eneroth P., Kjekshus J., et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation. 82:1990;730-736
13. Kim S.D. Measurement of the renin-angiotensin system in heart failure. Biol Res Nursing. 3:2000;210-226
14. Schunkert H., Dzau V., Tang S., et al. Increased rat cardiac angiotensin-converting activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest. 86:1990;1913-1920
15. Hirsch A.T., Talsness C.E., Schunkert H., et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 69:1991;475-482
16. Hirsch A., Talsness C.E., Smith A.D., et al. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation. 86:1992;1566-1574
17. Cody R. The integrated effects of angiotensin II. Am J Cardiol. 79:(5A):1997;9-11
18. Annarosa Y.L., Baosheng L., Wang X. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted cardiac myocytes. Circ Res. 82:1998;1145-1159
19. Laragh J.H. Hormones and the pathogenesis of congestive heart failure vasopressin, angiotensin-II: further evidence for renal-adrenal infarction from studies in hypertension and cirrhosis. Circulation. 25:1962;1015-1023
20. Ayers C.R. The effects of chronic hepatic venous congestion on the metabolism of d, l-aldosterone and d-aldosterone. J Clin Invest. 41:1962;884-895
21. Booz G.W., Baker K.M. Molecular signaling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 30:1995;537-543
22. Weber K.T., Sun Y., Tyagi S.C., et al. Collagen network of the myocardium: functional, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 26:1994;279-292
23. Campbell S.E. Collagen matrix in the heart. Eghbali-Webb M. Molecular biology of collagen matrix in the heart. 1994;1-21 R.G. Landes Co, Austin (TX)
24. Pelouch V., Dixon I.M.C., Golfman L., et al. Role of the extracellular matrix proteins in heart function. Mol Cell Biochem. 129:1994;101-120
25. Floras J.S. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 22:(Suppl A):1993;72A-84A
26. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:(13):1984;819-823
27. Metoprolol CR/XL Randomised Intervention Trial (MERIT). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007
28. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:(22):2001;1651-1658
29. Bristow M.R. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 101:2000;558-569
30. Simpson P.C., Karija K., Karns L.R., et al. Adrenergic hormones and control of cardiac myocyte growth. Mol Cell Biochem. 104:1991;35-43
31. Schaub M.C., Hefti M.A., Harder B.A., et al. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med. 75:1997;901-920
32. Kjaer A., Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol. 21:(6):2001;661-667
33. Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J. 32:1969;745-759
34. Goldsmith S. Baroreflex loading maneuvers do not suppress increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol. 19:1992;1180-1184
35. Share L. Interrelationships between vasopressin and the renin-angiotensin system. Federal Proceedings. 38:1979;2267-2271
36. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Annu Rev Physiol. 44:1992;479-602
37. Levin E., Gardner D., Samson W. Natriuretic peptides. N Engl J Med. 339:(5):1998;321-328
38. Wijeyaratne C., Moult P. The effects of α human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J Clin Endocrinol Metab. 76:1993;343-346
39. Hunt P., Espiner E., Nicholls M., et al. Different biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab. 81:1996;3871-3876
40. Schultz H., Gardner D., Deschepper C., et al. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol. 155:1988;R6-R13
41. Yang R., Jin H., Wyss J., et al. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension. 19:1986;198-205
42. Marin-Grez M., Fleming J., Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 324:1986;473-476
43. Fried T., McCoy R., Osgood R., et al. Effect of atriopeptin III on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiol. 250:1986;F1119-F1122
44. Stockand J., Sansom S. Regulation of filtration rate by glomerular mesangial cells in health and diabetic renal disease. Am J Kidney Dis. 29:1997;971-981
45. Harris P., Thomas D., Morgan T. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature. 326:1987;697-698
46. Zeidel M.L., Kikeri D., Silva P., et al. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest. 82:(3):1988;1067-1074
47. de Bold M., de Bold A. Stretch-secretion coupling in atrial cardiocytes: dissociation between atrial natriuretic factor release and mechanical activity. Hypertension. 18:(Suppl III):1991;169-178
48. Ambler K., Leite M. Regulation of atrial natriuretic peptide secretion by (α- adrenergic receptors: the role of different second messenger pathways). J Mol Cell Cardiol. 26:1994;391-402
49. Ogawa Y., Itoh H., Hakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharm Physiol. 22:1995;49-53
50. Chen H.H., Burnett J.C. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physcians. 111:1999;406-416
51. Gottlieb S., Kukin M., Ahern D., et al. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 13:1989;1534-1539
52. Omland T., Askraag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 96:1996;509-516
53. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction: comparison with plasma angiotensin II and endothelin-1. Eur Heart J. 20:1999;1799-1807
54. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203
55. Maeda K., Tsutamoto T., Wada A., et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 135:1998;825-832
56. Troughton R., Frampton C., Yandle T., et al. treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:(9210):2000;1126-1130
57. Murdoch D., McDonagh T., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentrations: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 138:(6):1999;1126-1132
58. Nicholls M., Lainchbury J., Richards A., et al. Brain natriuretic peptide-guided therapy for heart failure. Ann Med. 33:2001;422-427